Fresenius raised its earnings guidance, citing accelerating growth in its hospital and drug units, reinforcing a bullish case for the healthcare stock.
AstraZeneca shares fell on news of preliminary merger talks with Bristol Myers, sparking investor concerns over deal execution and antitrust risks.
AbbVie beat Q2 earnings estimates fueled by Botox demand revival, sending shares higher.
Shionogi-backed biotech Apnimed seeks to raise $160 million in a US IPO, highlighting investor appetite for sleep disorder treatments and cross-border healthcare…
Trump’s proposed 100% tariff on generic drugs from August 2028 shakes pharmaceutical stocks and raises fears of a new trade war front.
Apnimed, backed by Japanese drugmaker Shionogi, files IPO to raise capital for Phase 3 trial of oral sleep apnea therapy, targeting a…
AstraZeneca stock drops following unexpected failure of a heart disease drug trial.
Galderma shares sank after the FDA rejected its Botox rival Relfydess, delaying U.S. market entry and strengthening AbbVie's grip on the aesthetics…
Swiss President Keller-Sutter's meeting with USTR Greer aims to resolve US-Swiss tariff tensions that threaten Swiss exports in pharma and machinery, with…
Novo Holdings launches Europe-wide obesity drug incubators to strengthen Novo Nordisk's weight-loss R&D and challenge rivals in the booming GLP-1 market.
Apotex's $932 million IPO, priced at the top of the range, reflects strong demand for Canadian pharmaceutical stocks and could boost the…
Apotex's IPO is poised to price at the high end of its range, underscoring strong investor appetite for the Canadian generic drugmaker…